Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112962 | 0.91 | KMT2A (0.81) | KMT2AMEN1GAAL3MBTL1HSD17B10 | |
| SCHEMBL15976551 | 0.87 | ALDH1A1 (0.74) | KMT2AMEN1GAAL3MBTL1HPGD | |
| SCHEMBL28595517 | 0.87 | ALDH1A1 (0.78) | KMT2AMEN1GAAL3MBTL1HPGD | |
| SCHEMBL13419901 | 0.86 | ALDH1A1 (0.63) | KMT2AMEN1GAAALDH1A1CA12 | |
| SCHEMBL10279640 | 0.84 | PKM (0.67) | KMT2AMEN1GAAL3MBTL1HPGD | |
| SCHEMBL3392657 | 0.84 | GAA (0.76) | KMT2AMEN1GAAL3MBTL1HPGD | |
| SCHEMBL19752718 | 0.84 | GAA (0.76) | KMT2AMEN1GAAL3MBTL1HPGD | |
| SCHEMBL10112947 | 0.83 | HSD17B10 (0.69) | KMT2AGAAL3MBTL1HPGDHSD17B10 | |
| SCHEMBL19752674 | 0.81 | USP2 (0.71) | KMT2AMEN1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL5327469 | 0.81 | USP2 (0.71) | KMT2AMEN1HSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | KMT2A 3581/4885MEN1 4652/4885GAA 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.